Trial Profile
A Retrospective Study Investigating the Safety, Tolerability and Efficacy of Nintedanib Switched from Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2018
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2018 New trial record
- 23 May 2018 Results (data cut-off date: 4 Oct 2017) presented at the 114th International Conference of the American Thoracic Society.